DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prevention of Arrhythmia Device Infection Trial (PADIT)

Information source: Population Health Research Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Arrhythmia

Intervention: Incremental (Drug); Cefazolin (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Population Health Research Institute

Official(s) and/or principal investigator(s):
Dr. Andrew Krahn, M.D, Principal Investigator, Affiliation: University of British Columbia


The goal of the pilot study is to compare whether a centre-wide policy of incremental antibiotic therapy will reduce pacemaker infection compared to a policy of conventional antibiotic prophylaxis in high-risk patients undergoing arrhythmia device procedures. This pilot study will provide feasibility information for a larger cluster randomized crossover design (CRCD).

Clinical Details

Official title: Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Pilot Study

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention

Primary outcome: Hospitalization attributed to device infection

Detailed description: Multi-center, cluster crossover, unblinded, pilot study. Centers will be randomized to conventional vs. incremental antibiotic therapy for 2 months or until eligible 20 patients are treated, whichever comes first. At 2 months, centers will have a crossover period of 4 weeks where the alternate strategy is implemented, followed by the final 2-month/20 patient enrolment period. During each treatment period the randomized antibiotic strategy will be used on all center patients undergoing a device implant procedure. Prior to the planned surgery or at the first follow up visit, patients who meet the study eligibility criteria will be approached to obtain consent for data collection purposes. Follow up will be according to usual clinical care at the center.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- > 18 years

- received one of the following procedures:

1. a second or subsequent procedure on the arrhythmia device pocket: i. ICD, pacemaker, CRT-P, CRT-D generator and/or lead replacement. ii. pocket or lead revision iii. system upgrade (insertion or attempted insertion of leads) 2. new cardiac resynchronization therapy device implant (pacemaker or ICD) Exclusion Criteria:

- life expectancy < 12 months in the opinion of the local investigator.

- allergy or unable to tolerate cefazolin or clindamycin or vancomycin.

- allergy or unable to tolerate intracavitary bacitracin identified per-operatively.

- pre-operative identification that the patient has infection.

Locations and Contacts

Hamilton General Hospital, McMaster University, Hamilton, Ontario L8L 2X2, Canada

University of Ottawa Heart Institute, Ottawa, Ontario K1Y 4W7, Canada

Additional Information

Starting date: May 2011
Last updated: October 9, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017